Characterization of psoriasis patients in special body areas: real-world evidence from the Chinese Psoriasis Standardized Diagnosis and Treatment Center

被引:0
|
作者
Gao, Yuge [1 ,2 ]
Li, Chao [1 ]
Tong, Meng [1 ]
Hu, Yizhou [3 ]
Li, Yuzhen [1 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 2, Dept Dermatol, Harbin, Peoples R China
[2] Natl Clin Res Ctr Skin & Immune Dis, Beijing, Peoples R China
[3] Karolinska Inst, Dept Med Biochem & Biophys, Stockholm, Sweden
基金
国家重点研发计划;
关键词
Psoriasis; special body areas; real-world evidence; DISEASES; BURDEN; SCALE;
D O I
10.1080/09546634.2024.2337264
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
BackgroundWhile extensive research has provided a wealth of information on psoriasis in general, there remains a critical gap in understanding the unique characteristics of psoriasis in special body areas, such as the scalp, nails, palms, and genitals.ObjectiveTo investigate the characterization and treatment of psoriasis patients in special body areas.MethodsThe study was a retrospective analysis of patients with psoriasis enrolled in the Psoriasis Standardized Diagnosis and Treatment Center Project between January 2020 and September 2021.ResultsThe study encompassed 346 patients, 81% of them had psoriasis in at least two special body areas, with the nails as the most common area. Patients with genital psoriasis reported higher Dermatology Life Quality Index (DLQI) scores. A higher propensity for scalp and palmoplantar psoriasis was noted in patients with genital psoriasis. The proportion of patients treated with biologics rose, as the number of specific areas involved increased.ConclusionsPatients with genital psoriasis are more likely to have scalp and palmoplantar psoriasis. This study highlights the significant escalation in the proportion of biologics when the involvement of special body areas was >= 2.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Skin Clearance is Associated with Reduced Treatment Failure in Patients with Psoriasis: Real-World Evidence from the CorEvitas Psoriasis Registry
    Mclean, Robert R.
    Sima, Adam P.
    Beaty, Silky
    Low, Robert
    Spitzer, Rebecca L.
    Stark, Jeffrey L.
    Lesser, Elizabeth
    Lee, Edward
    Armstrong, April
    DERMATOLOGY AND THERAPY, 2023, 13 (11) : 2739 - 2751
  • [2] Skin Clearance is Associated with Reduced Treatment Failure in Patients with Psoriasis: Real-World Evidence from the CorEvitas Psoriasis Registry
    Robert R. McLean
    Adam P. Sima
    Silky Beaty
    Robert Low
    Rebecca L. Spitzer
    Jeffrey L. Stark
    Elizabeth Lesser
    Edward Lee
    April Armstrong
    Dermatology and Therapy, 2023, 13 : 2739 - 2751
  • [3] Impact of Disease Burden of Patients with Psoriasis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry
    Blauvelt, Andrew
    McLean, Robert R.
    Beaty, Silky W.
    Sima, Adam P.
    Low, Robert
    Stark, Jeffrey L.
    McClung, Laura
    Bagel, Jerry
    DERMATOLOGY AND THERAPY, 2024, 14 (10) : 2787 - 2804
  • [4] Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry
    Callis Duffin, Kristina
    Mason, Marc A.
    Gordon, Kenneth
    Harrison, Ryan W.
    Crabtree, Margaux M.
    Guana, Adriana
    Germino, Rebecca
    Lebwohl, Mark
    DERMATOLOGY, 2021, 237 (01) : 46 - 55
  • [5] Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World Evidence
    Malagoli, Piergiorgio
    Dapavo, Paolo
    Amerio, Paolo
    Atzori, Laura
    Balato, Anna
    Bardazzi, Federico
    Bianchi, Luca
    Cattaneo, Angelo
    Chiricozzi, Andrea
    Congedo, Maurizio
    Fargnoli, Maria Concetta
    Giofre, Claudia
    Gisondi, Paolo
    Guarneri, Claudio
    Lembo, Serena
    Loconsole, Francesco
    Mazzocchetti, Giampiero
    Mercuri, Santo Raffaele
    Morrone, Pietro
    Offidani, Anna Maria
    Palazzo, Giovanni
    Parodi, Aurora
    Pellacani, Giovanni
    Piaserico, Stefano
    Potenza, Concetta
    Prignano, Francesca
    Romanelli, Marco
    Savoia, Paola
    Stingeni, Luca
    Travaglini, Massimo
    Trovato, Emanuele
    Venturini, Marina
    Zichichi, Leonardo
    Costanzo, Antonio
    DERMATOLOGY AND THERAPY, 2024, 14 (10) : 2739 - 2757
  • [6] Real-world data on the use of secukinumab as treatment for moderate-to-severe psoriasis in Chinese patients
    He Huang
    Ming-Long Cai
    Xiao-Jie Hong
    Li-Jun Zheng
    Zhu-Lin Hu
    Tao Yuan
    Wei-Ran Li
    Yu-Jun Sheng
    Xue-Jun Zhang
    European Journal of Dermatology, 2020, 30 : 554 - 560
  • [7] Real-world data on the use of secukinumab as treatment for moderate-to-severe psoriasis in Chinese patients
    Huang, He
    Cai, Ming-Long
    Hong, Xiao-Jie
    Zheng, Li-Jun
    Hu, Zhu-Lin
    Yuan, Tao
    Li, Wei-Ran
    Sheng, Yu-Jun
    Zhang, Xue-Jun
    EUROPEAN JOURNAL OF DERMATOLOGY, 2020, 30 (05) : 554 - 560
  • [8] Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database
    Calapai, Fabrizio
    Ammendolia, Ilaria
    Cardia, Luigi
    Curro, Mariaconcetta
    Calapai, Gioacchino
    Esposito, Emanuela
    Mannucci, Carmen
    PHARMACEUTICS, 2023, 15 (07)
  • [9] Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
    Ruggiero, Angelo
    Picone, Vincenzo
    Martora, Fabrizio
    Fabbrocini, Gabriella
    Megna, Matteo
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2022, 15 : 1649 - 1658
  • [10] Does the Vehicle Matter? Real-World Evidence on Adherence to Topical Treatment in Psoriasis
    Teixeira, Ana
    Teixeira, Maribel
    Almeida, Vera
    Gaio, Rita
    Torres, Tiago
    Magina, Sofia
    Cunha, Catia
    Sousa Lobo, Jose M.
    Almeida, Isabel F.
    PHARMACEUTICS, 2021, 13 (10)